FDA approves Dupixent for chronic spontaneous urticaria in young children
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU).
May 5, 2026
0
6
